The products from each of these platforms address significant unmet medical needs. The Company's lead antisense compound, Genasense, is in late-stage clinical trials for treatment of melanoma, multiple myeloma and chronic lymphocytic leukemia. Other current studies with Genasense target acute myeloid leukemia and cancers of the prostate, lung, colon and breast. Genasense is being used to enhance the activity of other standard types of anticancer therapy. The drug has received both Fast Track and Orphan Drug designation from the United States Food and Drug Administration.
Revenues reflect the inclusion of licence revenues and royalty fees.
Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Some event data provided by StreetEvents . Data and information is provided for informational purposes only, and is not intended for trading purposes.